BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: South E, Cox E, Meader N, Woolacott N, Griffin S. Strimvelis® for Treating Severe Combined Immunodeficiency Caused by Adenosine Deaminase Deficiency: An Evidence Review Group Perspective of a NICE Highly Specialised Technology Evaluation. Pharmacoecon Open 2019;3:151-61. [PMID: 30334168 DOI: 10.1007/s41669-018-0102-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
Number Citing Articles
1 Aballéa S, Thokagevistk K, Velikanova R, Simoens S, Annemans L, Antonanzas F, Auquier P, François C, Fricke FU, Malone D, Millier A, Persson U, Petrou S, Dabbous O, Postma M, Toumi M. Health economic evaluation of gene replacement therapies: methodological issues and recommendations. J Mark Access Health Policy 2020;8:1822666. [PMID: 33144927 DOI: 10.1080/20016689.2020.1822666] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
2 Damase TR, Sukhovershin R, Boada C, Taraballi F, Pettigrew RI, Cooke JP. The Limitless Future of RNA Therapeutics. Front Bioeng Biotechnol 2021;9:628137. [PMID: 33816449 DOI: 10.3389/fbioe.2021.628137] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 6.0] [Reference Citation Analysis]
3 Ho JK, Borle K, Dragojlovic N, Dhillon M, Kitchin V, Kopac N, Ross C, Lynd LD. Economic Evidence on Potentially Curative Gene Therapy Products: A Systematic Literature Review. Pharmacoeconomics 2021;39:995-1019. [PMID: 34156648 DOI: 10.1007/s40273-021-01051-4] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 van den Berg AIS, Yun CO, Schiffelers RM, Hennink WE. Polymeric delivery systems for nucleic acid therapeutics: Approaching the clinic. J Control Release 2021;331:121-41. [PMID: 33453339 DOI: 10.1016/j.jconrel.2021.01.014] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
5 Lloyd-Williams H, Hughes DA. A systematic review of economic evaluations of advanced therapy medicinal products. Br J Clin Pharmacol 2021;87:2428-43. [PMID: 32154598 DOI: 10.1111/bcp.14275] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 10.0] [Reference Citation Analysis]
6 Linnik DS, Tarakanchikova YV, Zyuzin MV, Lepik KV, Aerts JL, Sukhorukov G, Timin AS. Layer-by-Layer technique as a versatile tool for gene delivery applications. Expert Opinion on Drug Delivery 2021;18:1047-66. [DOI: 10.1080/17425247.2021.1879790] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
7 Ma C, Wang Z, Xu T, He Z, Wei Y. The approved gene therapy drugs worldwide: from 1998 to 2019. Biotechnology Advances 2020;40:107502. [DOI: 10.1016/j.biotechadv.2019.107502] [Cited by in Crossref: 73] [Cited by in F6Publishing: 50] [Article Influence: 73.0] [Reference Citation Analysis]
8 van Overbeeke E, Michelsen S, Toumi M, Stevens H, Trusheim M, Huys I, Simoens S. Market access of gene therapies across Europe, USA, and Canada: challenges, trends, and solutions. Drug Discov Today 2021;26:399-415. [PMID: 33242695 DOI: 10.1016/j.drudis.2020.11.024] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]